We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

31 hedge funds and large institutions have $44.4M invested in Sinovac Biotech, Ltd in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,000% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 1

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

182% more funds holding

Funds holding: 11 → 31 (+20)

9% more capital invested

Capital invested by funds: $40.8M → $44.4M (+$3.55M)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
31
Holders Change
+20
Holders Change %
+181.82%
% of All Funds
0.52%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
21
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.54M
2
State Street
State Street
Massachusetts
+$1.04M
3
O
OrbiMed
New York
+$349K
4
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB)
Sweden
+$259K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$179K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$38.2M – – –
NAH
2
Neumann Advisory (HK)
Hong Kong
$2.04M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$1.54M +$1.54M +2,375,841 New
State Street
4
State Street
Massachusetts
$1.04M +$1.04M +160,875 New
YMRC
5
Yorktown Management & Research Company
Virginia
$485K – – –
O
6
OrbiMed
New York
$350K +$349K +2,718,735 New
Skandinaviska Enskilda Banken (SEB)
7
Skandinaviska Enskilda Banken (SEB)
Sweden
$259K +$259K +40,000 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$179K +$179K +27,717 New
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$108K +$108K +16,630 New
UBS Group
10
UBS Group
Switzerland
$59K +$59K +9,095 New
Northern Trust
11
Northern Trust
Illinois
$55K +$55K +13,787 New
Morgan Stanley
12
Morgan Stanley
New York
$26K +$26K +3,941 New
Wells Fargo
13
Wells Fargo
California
$19K +$19K +2,937 New
JP Morgan Chase
14
JP Morgan Chase
New York
$19K +$19K +3,000 New
IA
15
IFP Advisors
Florida
$8K – – –
Group One Trading
16
Group One Trading
Illinois
$3K +$3K +412 New
TFA
17
Transamerica Financial Advisors
Florida
$1K +$1K +2 New
Northwestern Mutual Wealth Management
18
Northwestern Mutual Wealth Management
Wisconsin
$1K +$1K +102 New
CS
19
Credit Suisse
Switzerland
$1K +$1K +656 New
FGAM
20
Financial Gravity Asset Management
Texas
$796 – – –

SVA Hedge Fund Activity: Q2 2022 in Review

31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2022, worth a combined $44.4M — up 8.7% from $40.8M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new SVA positions and 1 closed out — a net gain of 20 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.54M.

  • 31 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2022, up from 11 in Q1 2022.
  • Funds reported $44.4M of Sinovac Biotech, Ltd stock for Q2 2022, up 8.7% quarter-over-quarter.
  • 21 funds opened new Sinovac Biotech, Ltd positions in Q2 2022 and 1 closed out, a net change of +20 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q2 2022 was Renaissance Technologies, an estimated $1.54M added.

Based on aggregated 13F filings for Q2 2022.